The partnership enables Definiens to utilize the Visage CS enterprise visualization application in its forthcoming Definiens LymphExpert Version 2.0. By quantifying lymph nodes not only according to RECIST (Response Evaluation Criteria In Solid Tumors) and World health Organization (WHO) guidelines but also by their volume, the new integrated system allows for efficient lesion analysis including automated quantification of lymph nodes. Visage's technology provides Definiens LymphExpert Version 2.0 with a thin client-based interface for full local and remote access as well as universal connectivity to image acquisition devices and image archives.
"Visage CS provides an efficient workflow across different oncology applications. The platform's intuitive user interface concept allowed us to seamlessly pair it with the Definiens LymphExpert, resulting in an extremely fast and easy-to-use solution,” said Frank-P. Klein, vice president, medical imaging at Definiens. "As a result, radiologists can now easily compare changes in lymph node size over time and thus derive additional information about the efficacy of a given therapy.”
"Definiens Lymph Expert allows for new levels of automation and efficiency in lymph node analysis. Adding this technology to the Visage platform is one important step in responding to the trend towards more quantitative and standardized diagnostics,” stated Dr. Malte Westerhoff, CTO Visage Imaging.
"We are excited about this cooperation,” said David Chambers, CEO of Visage Imaging. "Definiens is one of the leading innovators in the area of image understanding and quantification. Their technology combined with our Thin Client based enterprise visualization platform will allow us to bring very attractive solutions to the clinical and preclinical imaging markets."
Visage Imaging is a global leading provider of scalable enterprise visualization, radiology information system (RIS) and picture archiving and communications system (PACS) solutions for clinical and preclinical imaging. Visage visualization and PACS solutions are registered as medical devices in Europe, Canada, and Australia, and have received U.S. Food and Drug Administration (FDA) clearance.
By automating image analysis, Definiens supports healthcare providers in analyzing and interpreting vast numbers of digital images accurately and consistently. Definiens improves the analysis of tissue samples and noninvasive imaging, enabling translational medicine--from early diagnosis to personalized treatment.
Related Links:
Definiens
Visage Imaging
